Cognito Therapeutics, a neurotechnology firm based in the U.S., has teamed up with Ochsner Health to create the Brain Health Collaboratory. Their goal is to improve care for cognitive decline and Alzheimer’s disease in the Gulf South region.
This initiative blends Cognito’s Spectris technology with Ochsner’s medical expertise to find new ways to support brain health, focusing on both urban and rural communities. Ochsner’s Neuroscience Institute, which caters to patients from Houston to Atlanta, will play a key role in this effort.
Ochsner is also planning a new 132,000-square-foot facility to enhance its neuroscience programs, with the Debra H. and Robert J. Patrick Neuroscience Institute opening later this year in New Orleans.
The Collaboratory aims to create a Brain Health Index. This framework will help track disease progress, cognitive health, and how patients respond to treatments. They will explore how the Spectris therapy fits into current healthcare systems, particularly for those eligible for both Medicare and Medicaid.
Cognito also hopes to assess the clinical and economic benefits of non-invasive therapies in value-based care. This effort builds on a similar partnership they initiated with West Virginia University’s Rockefeller Neuroscience Institute in late 2025.
Christian Howell, CEO of Cognito Therapeutics, emphasized the significance of this partnership. He noted that Ochsner’s vast reach allows them to deliver innovative brain health solutions to diverse populations. “Access to new therapies is crucial for generating real-world evidence, ultimately offering new options for people living with Alzheimer’s,” he stated.
Recent studies indicate that around 6.5 million Americans are currently living with Alzheimer’s, and that number could rise to 14 million by 2060. Efforts like the Brain Health Collaboratory could be instrumental in changing the trajectory of this growing health crisis.
For additional insights into Alzheimer’s disease and innovative therapies, you might find this report by the Alzheimer’s Association useful: Alzheimer’s Association Report.
